

# Department of Cell Biology and Anatomy

## Outline and Research Objectives

When our institution was reformed from School of Medicine to Graduate School of Medicine, Department of Cell Biology and Anatomy has been built with the transition from the previous department of Anatomy. Therefore, directions of researches in this department are molecular cell biology based on structural cell biology.

At the same time this department has high responsibility for education of medical students, students of other faculties, and master course and Ph.D. course students (totally 518 hours per year). The teaching covers lectures and laboratory courses of gross anatomy, neuroanatomy, histology, cell biology and developmental biology.

Main subjects of researches are focused on 1) the mechanisms of intracellular transport, 2) the mechanism of cell morphogenesis, and 3) roles of cytoskeleton on development.

To solve these problems we combine structural biological approaches such as various kinds of light microscopy, immunocytochemistry, quick freeze deep etch electron microscopy, cryoelectron microscopy, X-ray crystallography with molecular biology, biochemistry, molecular biophysics, electrophysiology and molecular genetics.

## Faculties and Students

Professor and Chair	Nobutaka Hirokawa, M. D., Ph.D. (from 1983~)
Associate Professor	Yoshimitsu Kanai, M. D., Ph. D. Takao Nakata, M. D., Ph. D.
Lecturer	Yasuko Noda, M. D., Ph. D. Sumio Terada, M. D., Ph. D.
Associate .....	8
Postdoctoral Fellow .....	2 (Japan), 1 (France), ..... 1 (China)
Graduate Students .....	7 (Japan), 2 (China)
Research Student .....	3 (China), 1 (Korea)
Secretary & Technician .....	4

## Past Research, Current Research and Major Accomplishments

### I. Rapid Freeze Deep Etch Electron Microscopy and Identification of New Groups of Crossbridge Structures Among Microtubules, Intermediate Filaments, Actin and Membranous Organelles.

Hirokawa has developed a new microscopic method which rapidly freeze cells and tissues by making contact with a pure copper block cooled with liquid nitrogen (-190 C) or helium (-269 C) in Japan. He further developed this method in USA with Dr. John Heuser and visualised as yet unknown aspects of specialized membrane structures such as Gap Junction, Tight Junction, and Neuromuscular Junctions. Further he discovered a group of new filamentous cross-bridges among microtubules, intermediate filaments,

actin filaments and membranous organelles. Combining immunocytochemistry, biochemistry, and in vitro reconstitution he proved the chemical nature of these structures as 1) fodrin and myosin in brush borders of intestinal cells, a model of cellular cortex, 2) MAP1A, MAP1B, MAP2 and Tau in microtubule domains in neuronal axon and dendrites, 3) elongated C-terminus of Neurofilament M and H proteins in neurofilament domains in neuronal axons, 4) Synapsin I associated with actin and synaptic vesicles in presynaptic terminals.

### II. Discovery of Kinesin Superfamily Proteins, KIFs and Elucidation of Mechanism of Intracellular Transport.

Hirokawa discovered various kinds of new filamentous structures between distinct kinds of membranous organelles and microtubules. He predicted these short crossbridges to be microtubule associated motor proteins carrying cargo vesicles along the microtubules.

The nerve axon is frequently very long (frequently ~1m long). Because of lack of protein synthesis machinery in the axon most of the proteins necessary in the axon and synaptic terminals ought to be transported down the axon as various kinds of membranous organelles and protein complexes after the synthesis in the cell body so that intracellular transport is fundamental for neuronal morphogenesis and functioning. At the same time because similar mechanism exists in every kinds of cells nerve cells serve as a good model system to elucidate this mechanism. Using molecular biology we discovered most of

kinesin superfamily motor proteins, KIFs which move along microtubule rails by hydrolysing ATP. Recently we identified all 45 kif genes in mammalian such as human and mouse. We have uncovered the structure, dynamics and functions of many members of KIFs using molecular cell biological, biophysical, structural biological and molecular genetic approaches.

### **KIFs in Axonal Transport**

KIF1A and KIF1B $\beta$  transport synaptic vesicle precursors anterogradely from cell body to synaptic terminals. They are fundamental for neuronal functioning and survival. Further, we showed using molecular genetic approaches that KIF1B $\beta$  is a responsible gene of human hereditary neuropathy Charcot-Marie-Tooth type 2A and proved that CMT2A is due to haploinsufficiency of functional KIF1B $\beta$  and decrease of synaptic vesicle protein transport.

KIF1B $\beta$ +/- mice serve as a model for CMT2A and we found a way of diagnosis and potential therapy of the symptom of this disease. KIF1B $\alpha$  and KIF5A, B, C redundantly convey mitochondria anterogradely. KIF3, composed of KIF3A and KIF3B heterodimer and associated protein KAP3, transports vesicles associated with a fodrin and important for neurite elongation through KAP3- $\alpha$  fodrin interaction. KIF2 and KIF4 are expressed specifically in juvenile neurons and functioning for neurite extension.

### **Receptor Transport in Dendrites**

Our studies revealed the mechanism of transport of receptors in dendrites.

KIF17 transports NMDA type glutamate receptor containing vesicles in dendrites toward microtubule plus ends through interaction between KIF17 C-terminal tail-Mint 1 (mLin10)- CASK (mLin2)- Velis (mLin7) and NR2B subunit of NMDA receptor. Furthermore, we showed by transgenic mouse strategy that KIF17 plays a significant role on memory and learning. KIF5A, B, C convey AMPA type glutamate receptor containing vesicles towards microtubule plus end through the interaction between KIF5 heavy chain - GRIP1 (glutamate receptor interacting protein 1)-GluR 2 subunit of AMPA type glutamate receptors.

These studies elucidated also for the first time long standing questions how KIFs recognize and bind to cargoes by showing KIF tail - scaffolding protein complex or adaptor protein complex- membrane protein interaction is a typical way. This idea was supported by our other study revealing that KIF13A transports Mannose 6- phosphate Receptor containing vesicles from Golgi to plasma membrane through the interaction between KIF13A tail - AP-1 adaptor protein complex and Mannose 6 phosphate receptors. Our study about the transport of AMPA type receptor by KIF5 also elucidated a mechanism how motor pro-

tein determines its direction, axon vs dendrites. GRIP1 steers KIF5 to dendrites via KIF5 heavy chain - GRIP1 interaction, while JSAP1 steers KIF5 to axon via KIF5 light chain- JSAP1 interaction.

### **KIF3 Determines Left-Right Asymmetry of Our Body**

Our gene targeting study of KIF3 (KIF3A-/-, and KIF3B-/-) significantly contributed for the elucidation of mechanism of determination of left-right asymmetry of our body, a very important hot problem in developmental biology. Our study uncovered that KIF3 motor is essential for left-right determination of our body through intraciliary transportation of protein complexes for the ciliogenesis of motile primary cilia that generate leftward unidirectional flow of extraembryonic fluid, "nodal flow", which could produce a concentration gradient of putative secreted morphogen in the extraembryonic fluid along the left-right axis in the node of early embryo, very important region for the determination of our body plan.


### **Mechanism of Motility of Monomeric Motor, KIF1A**

We have discovered monomeric motors KIF1 subfamily such as KIF1A, KIF1B  $\alpha$  and  $\beta$ . Because motors previously identified are all dimers such as conventional kinesin (KIF5), dyneins and myosin the prevailing hypothesis for how the motor moves processively for certain distance along rails was the hand over hand model, which means a motor needs two legs to move as we walk on the rail. We, however, discovered monomeric motor such as KIF1A. Because the monomeric motor is the simplest motor it is a good model system to study the basic mechanism of motility of KIFs. We showed using molecular biophysics approach that a single KIF1A motor can move processively for more than 1 $\mu$ m on microtubules. Furthermore, our study revealed that the processive movement of KIF1A is based on the biased Brownian movement. This is the first clear experimental demonstration showing that motor protein can move by the biased Brownian movement. We further elucidated why single leg motor can move processively along microtubules without dissociation. We found polylysine loop (K-loop) in loop12 and showed that this K-loop is critical for processive movement through the interaction with C-terminal flexible end of tubulin (E-hook) especially at the weak binding state (ADP state) by biophysics, and cryoelectron microscopy.


We further analysed how the plus end bias can be emerged by combination of cryoelectron microscopy and X-ray crystallography. We found that counter clockwise 20 degree rotation of motor domain from ADP to ATP like state is critical for plus end biased




KIF review (Hirokawa 1998)




Kinesin structure (Hirokawa et al. 1989)



KIF1A transports synaptic vesicle precursor (Okada et al. 1995)



KIF1B is responsible gene of hereditary neuropathy (Zhao et al., 2001)



KIF17 transports NMDA receptors (Setou et al. 2000)





Photobleaching recovery study of fluorescent tubulin (Okabe et al. 1990)




Tau induced microtubule bundles and process elongation (Kanai et al. 1989)



Tau/MAP1B double knockout mice (Takei et al. 2000)




KIF1A monomer moves processively by biased Brownian movement (Okada & Hirokawa Science 1999)




Cryo EM study of KIF1A motor domain-microtubule complex (Kikkawa et al. Cell 2000)

KIFs transport various kinds of cargoes in axon and dendrites



KIFs recognize and bind functional membraneproteins, through KIF tail-scaffolding protein/adaptor protein complex interaction (Setou et al. Science 2000, Nakagawa et al. Cell 2001, Setou et al. Nature 2002)



X-ray crystallography and cryoEM study of monomeric KIF1A motor domain (Kikkawa et al. Nature 2001)

movement of KIF1A monomeric motor.

### **Mechanism of Slow Axonal Transport**

Cytoskeletal proteins such as tubulin, actin and neurofilament triplet proteins (NFH, NFM, NFL) and some cytosolic proteins were known to be transported down the axon slowly at 1~2mm/day. Using 1) microinjection of fluorescein labelled cytoskeletal proteins and subsequent analysis by fluorescent photo-bleach recovery, 2) microinjection of caged-fluorescein labelled cytoskeletal proteins and subsequent analysis by UV-photoactivation in cultured neurons we showed most of cytoskeletal proteins such as tubulin and actin are transported as small oligomers. Further, recently using microinjection of fluorescein labelled tubulin and cytosolic proteins into squid giant axons and subsequent analysis with fluorescence confocal laser scanning microscopy and fluorescence correlation spectroscopy combined with microinjection of anti KIF antibodies we demonstrated that tubulin is transported as small oligomers by conventional kinesin (KIF5) as a motor.

### **III. Microtubule Associated Proteins (MAPs) and Mechanism of Neuronal Morphogenesis.**

Hirokawa identified various kinds of filamentous structures associated with microtubules by the quick freeze deep etch electron microscopy. The next questions were what are the chemical nature and what are the functions of these new structures. The microtubule associated proteins (MAPs) identified in brains were good candidates. Therefore, we have studied MAPs. We biochemically isolated major MAPs of mammalian brains such as MAP1A, MAP1B, MAP2 and tau, and studied molecular structure and localization. All these MAPs were filamentous flexible structures from 185 to 50nm in length dependent on the difference of molecular weight. Immunocytochemistry and in vitro reconstitution confirmed that these MAPs are components of filamentous structures associated with microtubules in neurons. To know the function of MAPs, we expressed tau and MAP2 in non neuronal cells such as fibroblasts and Sf9 cells by cDNA transfection. These studies showed that tau and MAP2 induce microtubule polymerization and bundling and process extension. They also revealed that C-terminal domain are critical for microtubule polymerization and N-terminal projection domain determines the different spacings between adjacent microtubules in microtubule domains in axon vs dendrites. These data suggest the important role of tau and MAP2 in formation of axon and dendrites. In order to elucidate function of MAPs in vivo we generated single knockout mice of tau, MAP1B, and MAP2 and analysed them. Generally, the phenotypes of single knockout mice were subtle. However, tau/MAP1B

and MAP2/MAP1B double knockout mice showed predominant disturbance of axonal elongation and dendritic elongation respectively. Cellular bases of these phenotypes are suppression of microtubule stability and bundle formation in growth cones of axon and dendrites leading to the inhibition of proper neurite extension and neuronal cell migration. Thus, our studies revealed Tau/MAP1B and MAP2/MAP1B synergistically play fundamental roles in axonal and dendritic formation respectively.

### **Future Prospects**

The further studies in near future will include following subjects as the continuation of on going researches.

#### **I. Mechanism of Intracellular Transport**

- 1) The functions of new KIFs especially in neurons, epithelial cells and fibroblasts to elucidate yet unknown mechanism of intracellular transport of various kinds of membranous organelles, protein complexes and mRNA.
- 2) Understanding how each KIFs recognize and bind their specific cargoes.
- 3) The studies how the binding and unbinding of KIFs with cargoes are regulated.
- 4) The mechanism how neurons determine the direction of transport by KIFs, toward axon vs dendrites.
- 5) The study of relationship between KIFs and neuronal functions such as memory and learning by molecular genetic approach.
- 6) The relationship between KIFs and diseases using molecular genetical approaches.
- 7) The detailed mechanism of motility of KIF1A motor using structural biology and molecular biophysics.

#### **II. Mechanism of Neuronal Morphogenesis and MAPs**

Using molecular genetical approaches we will unravel the function of MAP1A, one member of major MAPs whose function has been unknown.

### **Research Grants**


1. Center of Excellence (COE) grant from the Ministry of Education, Culture, Science and Sports, "Molecular Cell Biological and Molecular Genetical Study of the Cytoskeleton: Mechanism of Intracellular Transport, Signal Transmission and Cellular Morphogenesis." From April 1996 to March 2001. 1,885,000,000 yen
2. Grant in Aid for Basic Research, "Molecular Cell Biology of New Molecular Motors, KIFs," from the Ministry of Education, Culture, Science and Sports. From April 1996 to March 1999. 34,500,000 yen
3. Center of Excellence (COE) grant from the Ministry of Education, Culture, Science, Sports and Technology, "Mechanism of Intracellular Transport

:Molecular Cell Biology, Structure Biology and Molecular Genetics."From April 2001 to March 2006. 2,020,000,000 yen

## Publication list

1. Hirokawa N and Kirino T. An ultrastructural study of nerve and glia cells by freeze-substitution. *Journal of Neurocytology* 9, 243-254, 1980.
2. Hirokawa N. Crosslinker system between neurofilaments, microtubules and membranous organelles in frog axons revealed by quick freeze, freeze fracture, deep etching method. *Journal of Cell Biology* 94, 129-142, 1982.
3. Hirokawa N, and Heuser J. E. The inside and outside of gap junction membranes visualized by deep etching. *Cell* 30, 395-406, 1982.
4. Hirokawa N, Cheney R, and Willard M B. Location of a protein of the fodrin-spectrin-TW 260/240 family in the mouse intestinal brush border. *Cell* 32, 953-965, 1983.
5. Hirokawa N, M. A. Glicksman, and M. B. Willard. Organization of mammalian neurofilament polypeptides within the neuronal cytoskeleton. *Journal of Cell Biology* 98, 1523-1536, 1984.
6. Shiomura Y and Hirokawa N. The molecular structure of microtubule-associated protein 1A (MAP1A) in vivo and in vitro. An immunoelectron microscopy and quick-freeze, deep-etch study. *Journal of Neuroscience* 7, 1461-1469, 1987.
7. Hirokawa N, Hisanaga S and Shiomura Y. MAP2 is a component of crossbridges between microtubules and neurofilaments in vivo and in vitro. Quick-freeze, deep etch immunoelectron microscopy and reconstitution studies. *Journal of Neuroscience* 8, 2769-2779, 1988.
8. Hirokawa N, Pfister K K, Yorifuji H, Wagner MC, Brady S T and Bloom GS. Submolecular domains of bovine brain kinesin identified by electron microscopy and monoclonal antibody decoration. *Cell* 56, 867-878, 1989.
9. Kanai Y, Takemura R, Ohshima T, Mori H, Ihara Y, Yanagisawa M, Masaki T and Hirokawa N. Expression of multiple tau isoforms and microtubule bundle formation in fibroblasts transfected with a single tau cDNA. *Journal of Cell Biology* 109, 1173-1184, 1989.
10. Sato-Yoshitake R, Shiomura Y, Miyasaka H and Hirokawa N. Microtubule-associated protein 1B: Molecular structure, localization, and its phosphorylation-dependent expression in developing neurons. *Neuron* 3, 229-238, 1989.
11. Okabe S and Hirokawa N. Turnover of fluorescently labeled tubulin and actin in the axon. *Nature* 343, 479-482, 1990.
12. Hirokawa N, Yoshida T, Sato-Yoshitake R, and Kawashima T. Brain dynein (MAP1C) localizes on both anterogradely and retrogradely transported membranous organelles. *Journal of Cell Biology* 111, 1027-1037, 1990.
13. Hirokawa N, Sato-Yoshitake R, Kobayashi N, Pfister KK, Bloom GH, and Brady ST. Kinesin associates with anterogradely transported membranous organelles in vivo. *Journal of Cell Biology* 114, 295-302, 1991.
14. Aizawa H, Sekine Y, Takemura R, Zhang Z, Nangaku M and Hirokawa N. Kinesin family in murine central nervous system. *Journal of Cell Biology* 119, 1287-1296, 1992.
15. Chen J, Kanai Y, Cowan NJ and Hirokawa N. Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. *Nature* 360, 674-677, 1992.
16. Hirokawa N. Microtubule organization and dynamics dependent on microtubule-associated proteins. *Current Opinion in Cell Biology* 6, 74-82, 1994.
17. Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T, Sato-Yoshitake R, Takei Y, Noda T and Hirokawa N. Altered microtubule organization in small-calibre axons of mice lacking tau protein. *Nature* 369, 488-491, 1994.
18. Kondo S, Sato-Yoshitake R, Noda Y, Aizawa H, Nakata T, Matsuura Y and Hirokawa N. KIF3A is a new microtubules-based anterograde motor in the nerve axon. *Journal of Cell Biology* 125, 1095-1107, 1994.
19. Sekine Y, Okada Y, Kondo S, Aizawa H, Takemura R and Hirokawa N. A novel microtubule-based motor protein (KIF4) for organelle transports, whose expression is regulated developmentally. *Journal of Cell Biology* 127, 187-202, 1994.
20. Nangaku M, Sato-Yoshitake R, Okada Y, Noda Y, Takemura R, Yamazaki H, and Hirokawa N. KIF1B; A novel microtubule plus end-directed monomeric motor protein for transport of mitochondria. *Cell* 79, 1209-1220, 1994.
21. Noda Y, Sato-Yoshitake R, Kondo S, Nangaku M and Hirokawa N. KIF2 is a new microtubule-based anterograde motor that transports membranous organelles distinct from those carried by kinesin heavy chain or KIF3A/B. *Journal of Cell Biology* 129, 157-167, 1995.
22. Okada Y, Yamazaki H, Sekine Y, and Hirokawa N. The neuron-specific kinesin superfamily protein KIF1A is a unique monomeric motor for anterograde axonal transport of synaptic vesicle precursors. *Cell* 81, 769-780, 1995.
23. Kikkawa M, Ishikawa T, Wakabayashi T and Hirokawa N. Three-dimensional structure of the kinesin head-microtubule complex. *Nature* 376, 274-276, 1995.
24. Yamazaki H, Nakata T, Okada Y, and Hirokawa N. KIF3A/B: A heterodimeric kinesin superfamily protein that works as a microtubule plus end-directed motor for membrane organelle transport. *Journal of Cell Biology* 130, 1387-1399, 1995.
25. Hirokawa N. Organelle transport along microtubules—the role of KIFs (Kinesin superfamily proteins). *Trends in Cell Biology* 6, 135-141, 1996.

26. Terada S, Nakata T, Peterson A and Hirokawa N. Visualization of slow axonal transport in vivo. *Science* 273, 784-788, 1996.
27. Saito N, Okada Y, Noda Y, Kinoshita Y, Kondo S and Hirokawa N. KIFC2 is a novel neuron-specific C-terminal type kinesin superfamily motor for dendritic transport of multivesicular body-like organelles. *Neuron* 18, 425-438, 1997.
28. Takei Y, Kondo S, Harada A, Inomata S, Noda T and Hirokawa N. Delayed development of nervous system in mice homozygous for disrupted microtubule-associated protein 1B (MAP1B) gene. *Journal of Cell Biology* 137, 1615-1626, 1997.
29. Hirokawa N. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. *Science* 279, 519-526, 1998.
30. Nakata T, Terada S and Hirokawa N. Visualization of the dynamics of synaptic vesicle and plasma membrane proteins in living axons. *Journal of Cell Biology* 140, 659-674, 1998.
31. Yonekawa Y, Harada A, Okada Y, Kanai Y, Takei Y, Funakoshi T, Terada S, Noda T and Hirokawa N. Defect in synaptic vesicle precursor transport and neuronal cell death in KIF1A motor protein-deficient mice. *Journal of Cell Biology* 141, 431-441, 1998.
32. Tanaka Y, Kanai Y, Okada Y, Nonaka S, Takeda S, Harada A and Hirokawa N. Targeted disruption of mouse conventional kinesin heavy chain, KIF5B, results in abnormal perinuclear clustering of mitochondria. *Cell* 93, 1147-1158, 1998.
33. Nonaka S, Tanaka Y, Okada Y, Takeda S, Harada A, Kanai Y, Kido M and Hirokawa N. Randomization of left-right asymmetry due to loss of nodal cilia generating leftward flow of extraembryonic fluid in mice lacking KIF3B motor protein. *Cell* 95, 829-837, 1998.
34. Okada Y and Hirokawa N. A processive single-headed motor: kinesin superfamily protein, KIF1A. *Science* 283, 1152-1157, 1999.
35. Takeda S, Yonekawa Y, Tanaka Y, Okada Y, Nonaka S and Hirokawa N. Left-right asymmetry and kinesin superfamily protein KIF3A: New insights in determination of laterality and mesoderm induction by Kif3A<sup>-/-</sup> mice analyses. *Journal of Cell Biology* 145, 825-836, 1999.
36. Okada Y, Nonaka S, Tanaka Y, Saijoh Y, Hamada H and Hirokawa N. Abnormal nodal flow precedes situs inversus in iv and inv mice. *Molecular Cell* 4, 459-468, 1999.
37. Okada Y and Hirokawa N. Mechanism of the single-headed processivity : Diffusional anchoring between "k-loop" of kinesin and the C-terminus of tubulin. *Proceedings of the National Academy of Science of the USA* 97, 640-645, 2000.
38. Kikkawa M, Okada Y and Hirokawa N. 15Å resolution model of the monomeric kinesin motor: KIF1A. *Cell* 100, 241-252, 2000.
39. Takeda S, Yamazaki H, Seog D-H, Kanai Y, Terada S and Hirokawa N. KIF3 motor transports fodrin-associating vesicles important for neurite building. *Journal of Cell Biology* 148, 1255-1266, 2000.
40. Setou M, Nakagawa T, Seog D-H and Hirokawa N. Kinesin superfamily motor protein KIF17 and mLin-10 in NMDA receptor-containing vesicle transport. *Science* 288, 1796-1802, 2000.
41. Takei Y, Teng J, Harada A and Hirokawa N. Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. *Journal of Cell Biology* 150, 989-1000, 2000.
42. Terada S, Kinjo M and Hirokawa N. Oligomeric tubulin in large transporting complex is transported via kinesin in squid giant axons. *Cell* 103, 141-155, 2000.
43. Nakagawa T, Setou M, Seog D-H, Ogasawara K, Dohmae N, Takio K and Hirokawa N. A novel kinesin superfamily motor, KIF13A, transports mannose-6-phosphate receptor to plasma membrane through direct interaction with AP-1 complex. *Cell* 10, 569-581, 2000.
44. Kikkawa M, Sablin EP, Okada Y, Yajima H, Fletterick RJ and Hirokawa N. Switch-based mechanism of kinesin motors. *Nature* 411, 439 - 445, 2001.
45. Zhao C, Takita J, Tanaka Y, Setou M, Nakagawa T, Takeda S, Hong W-Y, Terada S, Nakata T, Takei Y, Saito M, Tsuji S, Hayashi Y and Hirokawa N. Charcot-Marie-Tooth Disease type 2A caused by mutation in a microtubule motor KIF1Bβ. *Cell* 105, 587-597, 2001.
46. Miki H, Setou M, Kanashiro K and Hirokawa N. All kinesin superfamily protein, KIF, genes in mouse and human. *Proceedings of the National Academy of Science of the USA* 98, 7004-7011, 2001.
47. Teng J, Takei Y, Harada A, Nakata T, Chen J and Hirokawa N. Synergistic effects of MAP2 and MAP1B knockout in neuronal migration, dendritic outgrowth, and microtubule organization. *Journal of Cell Biology* 15, 65-76, 2001.
48. Noda Y, Okada Y, Saito N, Setou M, Xu Y, Zhang Z and Hirokawa N. KIFC3, a microtubule minus end-directed motor for the apical transport of annexin XIIIb-associated Triton-insoluble membranes. *Journal of Cell Biology* 155, 77-88, 2001.
49. Setou M, Seog D-H, Tanaka Y, Kanai Y, Takei Y, Kawagishi M and Hirokawa N. Glutamate-receptor-interacting protein GRIP1 directly steers kinesin to dendrites. *Nature* 417, 83-87, 2002.
50. Harada A, Teng J, Takei Y, Oguchi K and Hirokawa N. MAP2 is required for dendrite elongation, PKA anchoring in dendrites, and proper PKA signal transduction. *Journal of Cell Biology* 15, 541-549, 2002.



# Department of Molecular Biology

## Outline and Research Objectives

This department was established in 1893 as the first Biochemistry Department in Japan. Since then, this department has been devoted to biochemical studies on vitamin, oxidative phosphorylation, lipid, carbohydrate and nucleic acid metabolisms, making remarkable contributions to advancements in medical biochemistry. After H. Okayama succeeded Chair in 1992, research has been focused on cancer, the cell cycle and differentiation in order to understand the molecular mechanism of malignant transformation and growth control.

## Faculties and Students

Professor and Chair	Hiroto Okayama, MD & PhD (1992~)
Associate .....	3
Postdoctoral Fellow .....	1
Graduate Student.....	5
Research Student .....	5
Secretary .....	2

## Past Research and Major Accomplishments

### *Development of high-efficiency full-length cDNA cloning method and eukaryotic expression cDNA cloning system*

Most of our past and current research stemmed from the development of the full-length cDNA cloning method and the cDNA expression cloning vector system that was done in the early 1980s by Hiroto Okayama and Paul Berg (Fig. 1)(1,2).

The full-length cDNA cloning method and the cDNA expression libraries constructed thereby have been used to clone numerous functional genes in laboratories over the world, the earliest one of which is the human Lesch-Nyhan syndrome causative gene (3). The cDNA expression cloning vector system was originally designed to clone genes on the basis of the

functions they express in a wide range of host cells, from fission yeast up to mammalian cells. This was enabled by development of highly efficient methods for introducing cDNA libraries into mammalian cells and fission yeast and construction of vectors specialized for library transduction into fission yeast (Fig. 1) (8, 10, 11). One of the most successful applications of this expression cloning system was isolation of human orthologues of several key cell cycle regulators initially found in fission yeast. Paul Nurse cloned the human *cdc2* cDNA from one of our expression libraries on the basis of trans-complementation of a fission yeast temperature-sensitive mutant of *cdc2*<sup>+</sup> essential for mitosis, and we cloned human orthologues of *wee1*<sup>+</sup> and *cdc25*<sup>+</sup> genes (13, 14), which critically regulate Cdc2 kinase during this transition, as described below.

### *Cell cycle control*

Cdc2 kinase is a protein kinase required for the onset of mitosis, initially found in fission yeast, but present in all eukaryotes. This kinase, associated with cyclins, is regulated by inhibitory tyrosine phosphorylation and activating dephosphorylation by Wee1 kinase and Cdc25 phosphatase, constituting a core element of DNA damage-responsive cell cycle checkpoint control for the G<sub>2</sub>-M transition in fission yeast.




Fig.1. Methods for construction of full-length expression cDNA librareis and trans-complementation cloning with fission yeast as host




Fig. 2. Similarity in DNA damage-invoked G1/G2 checkpoint control

The identification of human orthologues (*cdc2*, *wee1* and *cdc25B*) of these fission yeast cell cycle regulators demonstrated the evolutionary conservation of a cell cycle control system up to mammals (13, 14, 30). Using the same expression cloning system, we also identified an additional mammalian homologue (*cdc25A*) of *cdc25<sup>+</sup>* gene, which was found to play an unexpected role (23).

This gene is expressed in early G<sub>1</sub> and required for the cell cycle start. Search for targets for this novel phosphatase led us to discover that Cdk4, a cyclin-dependent kinase essential for the cell cycle start, is regulated by tyrosine phosphorylation and that its regulation constitutes a key part of DNA damage-induced G<sub>1</sub> checkpoint arrest during cell cycle entry from quiescence (23, 28, 37), revealing the presence of mirror image mechanisms for controlling DNA damage-responsive G<sub>1</sub> and G<sub>2</sub> checkpoint arrest in mammals (Fig. 2).

In addition to the studies on mammalian cell cycle control, we identified genes for 11 fission yeast novel cell cycle factors and cyclin G a novel mammalian cyclin (22), which control the G<sub>1</sub>-S transition, DNA-replication checkpoint or the formation and maintenance of sister chromatid cohesion (20, 24-27, 29, 33, 35, 40, 42-44, 48). Recent studies on two newly identified factors Eso1 and Pds5 involved in the formation of sister chromatid cohesion led us to discover that sister chromatid cohesion is formed and maintained by a highly unexpected mechanism, which functions as a molecular zipper and thereby promotes the formation of cohesions only between sister chromatids (48). This finding provided a new clue to the understanding of the mechanism for the genetic instability associated with malignant transformation.

### Differentiation control

One of the aspects of the cell we have been interested in understanding concerning carcinogenesis is differentiation control. To this end, we also used fission yeast as a model organism and discovered five novel genes controlling the commitment to differenti-

ation. They encode Esc1 a MyoD-like helix-loop-helix protein, Nrd1 an RNA-binding protein, Phh1 a stress MAP kinase similar to p38, Rcd1 an evolutionally conserved protein and Pas1 and Cyc17 novel cyclins (21, 26, 31, 33, 36, 43, 44). These proteins were found to be a modifier of cyclin AMP signaling, a determinant of the threshold to nutrient starvation for the commitment to differentiation, a stress signal transducer as an absolute requirement for the differentiation commitment, a key mediator of nitrogen starvation signal and factors that ensure mutual exclusiveness between the cell cycle start and the commitment to differentiation. In addition, using trans-complementation cloning, we isolated a human functional counterpart of the RNA-binding protein with predicted functions, which were shown in hematopoietic cells (38).

Furthermore, we recently found that the mammalian counterpart of Rcd1 is a novel transcriptional cofactor mediating retinoic acid-induced cell differentiation and is deeply involved in mouse lung development (50). These findings not only reveal remarkable conservation of the differentiation commitment system as well as the key elements that control the commitment step from yeast up to mammals (Fig. 3), but also greatly help understand the highly complex mechanism controlling the differentiation commitment in mammals.

### Anchorage-independent cell cycle start: a key mechanism for malignant transformation

One of the fundamental phenotypes that distinguish malignant from benign cells is the metastatic capability, which is underlain by the acquirement of the ability to perform S phase entry in the absence of anchorage. In the late 1980s, we began studies to understand the nature and mechanism of the acquirement of this unique property upon malignant transformation, by using growth factor-transformable NRK cells as a model system. The generally held concept was that anchorage-independent S phase entry is a mere consequence of excessive activation of growth signaling or defects in a growth arrest system, which






Fig. 3. Elements and evolutionary conservation of eukaryotic differentiation commitment control




Fig.4. Cell cycle start control by anchorage

are caused by activation of oncogenes and inactivation of recessive oncogenes. For the past 10 years, we studied genetically and cytologically the properties of oncogenically stimulated NRK cells and came to the several remarkable conclusions: 1) In NRK cells, epidermal growth factor and platelet-derived growth factor signals merge into a common pathway composed of CrkII, Ras and Raf-1, through which many oncogenes induce transformation; 2) Activation of this pathway induces anchorage-independent S phase entry in a synchronized fashion, but is dispensable for cell proliferation in the presence of anchorage; 3) Oncogenic stimulation recruits Cdk6 to participate in an essential step of anchorage-independent S phase onset; 4) Activation of G<sub>1</sub> cyclin-dependent kinases (Cdk4/6, Cdk2) is insufficient to induce anchorage-independent S phase onset (15, 16, 32, 39). Recently, we found that Cdc6, a key protein for the activation of replication origins, requires anchorage or oncogenic stimulation for its expression, which is regulated at the levels of transcription and proteolysis via a calpain-like protease, and moreover, that G<sub>1</sub> cyclin-dependent kinases and Cdc6 constitute key targets for controlling the G<sub>1</sub>-S transition by anchorage and oncogenic signals (Fig. 4)(49).

We believe that this latest finding would provide a

major breakthrough toward the understanding of the mechanisms for anchorage loss-invoked restriction of S phase onset and oncogenically induced anchorage-independent S phase onset, the latter being responsible for the metastatic capability of malignant cells. In addition, all these findings taken together raise the possibility that oncogenic transformation is not merely resulted from a failure to arrest due to excessive growth stimulation or defective cell cycle arrest systems, but from constitutive activation of a dormant mechanism that is present in normal cells and enables the cell cycle start in the absence of anchorage (46).

### Current Research

We are currently devoting most of our efforts to the understanding of how Cdc6 expression is regulated by anchorage and oncogenic signals.

#### Requirement for PI3 kinase in Cdc6 expression

It has been known that phosphoinositol-3 (PI3) kinase is required for the cell cycle start and one of its targets is p27 cyclin-dependent kinase inhibitor. We recently found that entirely independent from p27 downregulation, Cdc6 requires PI3 kinase for its expression during anchorage-dependent, but not

anchorage-independent, S phase entry. Treatment of cells with a specific PI3 kinase inhibitor shuts off Cdc6 expression despite E2F activation, but interestingly this shutoff is overridden by oncogenic stimulation. Further analysis is underway to identify how PI3 kinase and anchorage signal cooperate to express Cdc6.

### ***Identification of the protease responsible for the Cdc6 degradation and its regulation***

The most crucial point in understanding the regulatory mechanism of Cdc6 expression by anchorage and oncogenic stimulation is identification of the responsible protease and its regulatory mechanism (Fig.4). To this end, a human cdc6 cDNA was isolated, tagged with a histidine tag and transcribed in vitro and expressed in reticulocyte lysates, and the expressed His-tagged Cdc6 protein was purified by affinity chromatography in order to establish an in vitro assay system. Analysis of the nature of the putative protease suggests that the cells arrested in G<sub>1</sub> by anchorage loss contain the proteolytic activity that seems to be responsible for Cdc6 degradation. Analysis of the nature of this protease and its regulation is currently in progress.

### ***Cdk6-cyclin D3 as a highly potent sensitizer of cells to chemical and physical transformation***

We recently found that among D-type cyclin (D1, D2, D3) and partner kinase (Cdk4, Cdk6) combinations, the Cdk6-D3 complex is unique and can evade inhibition by p27 and p21, consequently enabling this complex to control proliferation competence under growth suppressive conditions (47). This finding led us to investigate the possible effects of the elevated expression of this complex on cell's susceptibility to malignant transformation, and we have found that 2-5 fold overexpression of Cdk6-D3 elevates 10<sup>3</sup>-10<sup>6</sup> folds the susceptibility of rodent fibroblasts to UV irradiation- or 3-methylcholanthrene-induced malignant transformation. Analysis is in progress to understand this sensitization mechanism.

### **Future Prospects**

There are three key questions regarding malignant transformation: 1) What is the mechanism by which transformed cells acquire the ability to perform anchorage-independent S phase onset as a basis for metastatic capability?; 2) What causes the genetic instability of cancer, which is believed to be a driving force for malignant progression and what are the key cell cycle factors activated or inactivated during this process?; 3) What is the mechanism for dedifferentiation of malignant cells? We believe that the series of our research will certainly offer critical clues to solve

these questions. We particularly believe that the finding that Cdc6, a key factor for the activation of replication origins, absolutely requires anchorage or oncogenic stimulation for its expression is a major breakthrough to understanding the central mechanism of oncogenically induced anchorage-independent S phase onset.

### **Research Grants**


1. H. Okayama, Grant-in-Aid for Scientific Research (A), JSPS, 1992-present. ¥10,000,000 a year.
2. H. Okayama, Grant-in-Aid for Scientific Research on Priority Areas "Advanced Cancer Research", MEXT, 1992-1999. ¥32,000,000 a year.
3. H. Okayama, Grant-in-Aid for Scientific Research on Priority Areas "Cell Cycle Control", MEXT, 2000-present. ¥60,000,000 a year.

### **Select Publications**

1. Okayama, H., and Berg, P. High efficiency cloning of full length cDNA. *Mol. Cell. Biol.* 2, 161-170, 1982.
2. Okayama, H., and Berg, P. A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells. *Mol. Cell. Biol.* 3, 280-289, 1983.
3. Jolly, D. J., Okayama, H., Berg, P., Esty, A. C., Filpula, D., Bohlen, P., Johnson, G., and Friedman, T. Isolation and characterization of a full length, expressible cDNA for human hypoxanthine guanine phosphoribosyl transferase. *Proc. Natl. Acad. Sci. USA* 80, 477-481, 1983.
4. Chin, D. J., Gil, G., Russell, D. W., Liscum, L., Luskey, K., Basu, S., Okayama, H., Berg, P., Goldstein, J. L., and Brown, M. Nucleotide sequence of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, a glycoprotein of endoplasmic reticulum. *Nature* 308, 613-617, 1984.
5. Yang, Y.-C., Okayama, H., and Howley, P. Bovine papillomavirus contains multiple transforming genes. *Proc. Natl. Acad. Sci. USA* 82, 1030-1034, 1985.
6. Okayama, H., Kawaiichi, M., Brownstein, M., Lee, F., Yokota, T., and Arai, K. High-efficiency cloning of full length cDNA; Construction and screening of cDNA expression libraries for mammalian cells. *Methods Enz.* 154, 3-28, 1987.
7. Chen, C., and Okayama, H. High-efficiency transformation of mammalian cells by plasmid DNA. *Mol. Cell. Biol.* 7, 2745-2752, 1987.
8. Okayama, H., and Chen, C. Calcium phosphate mediated gene transfer into established cell lines. *Methods Mol. Biol.* pp. 15-21, 1990.
9. Tanaka, K., Miura, N., Satokata, I., Miyamoto, I., Yoshida, M., Sato, Y., Kondo, S., Yasui, A., Okayama, H., and Okada, Y. A cDNA sequence of xeroderma pigmentosum group A gene encoding a protein with zinc finger structure. *Nature* 348, 73-76, 1990.

10. Inoue, H., Nojima, H., and Okayama, H. High efficiency transformation of *Escherichia coli* with plasmids. *Gene* 96, 23-28, 1990.
11. Okazaki, K., Okazaki, N., Kume, K., Jinno, S., Tanaka, K., and Okayama, H. High-frequency transformation method and library transducing vectors for cloning mammalian cDNAs by trans-complementation of *Schizosaccharomyces pombe*. *Nuc. Acids Res.* 18, 6485-6489, 1990.
12. Takamizawa, A., Mori, C., Fuke, I., Manabe, S., Murakami, S., Fujita, J., Onishi, E., Andoh, T., Yoshida, I., and Okayama, H. Structure and organization of the hepatitis C virus genome isolated from human carriers. *J. Virol.* 65, 1105-1113, 1991.
13. Nagata, A., Igarashi, M., Jinno, S., Suto, K., and Okayama, H. An additional homolog of the fission yeast *cdc25+* gene occurs in human and is highly expressed in some cancer cells. *New Biologist* 3, 959-968, 1991.
14. Igarashi, M., Nagata, A., Jinno, S., Suto, K., and Okayama, H. *Wee1+*-like gene in human cells *Nature* 353, 80-83, 1991.
15. Masuda, A., Kizaka-Kondoh, S., Miwatani, H., Terada, Y., Nojima, H., and Okayama, H. Signal transduction cascade shared by epidermal growth factor and platelet-derived growth factor is a major pathway for oncogenic transformation in NRK cells. *New Biologist* 4, 489-503, 1992.
16. Kume, K., Jinno, S., Miwatani, H., Kizaka-Kondoh, S., Terada, Y., Nojima, H., and Okayama, H. Oncogenic signal-induced ability to enter S phase in the absence of anchorage is the mechanism for the growth of transformed NRK cells in soft agar. *New Biologist* 4, 504-511, 1992.
17. Kimura, T., Tanizawa, O., Mori, K., Brownstein, M., and Okayama, H. Structure and expression of a human oxytocin receptor. *Nature* 356, 526-529, 1992.
18. Tatsuka, M., Mitsui, H., Wada, M., Nagata, A., Nojima, H., and Okayama, H. Elongation factor-1a gene determines susceptibility to transformation. *Nature* 359, 333-336, 1992.
19. Kizaka-Kondoh, S., Sato, K., Tamura, K., Nojima, H., and Okayama, H. Raf-1 protein kinase is an integral component of the oncogenic signal cascade shared by epidermal growth factor and platelet-derived growth factor. *Mol. Cell. Biol.* 12, 5078-5086, 1992.
20. Tanaka, K., Okazaki, K., Okazaki, N., Ueda, T., Sugiyama, A., Nojima, H. and Okayama, H. A new *cdc* gene required for S phase entry of *Schizosaccharomyces pombe* encodes a protein similar to the *cdc10+* and *SWI4* gene products. *EMBO J.* 11, 4923-4932, 1992.
21. Benton, B. K., Reid, M. S. and Okayama, H. A *Schizosaccharomyces pombe* gene that promotes sexual differentiation encodes a helix - loop - helix protein with homology to MyoD. *EMBO J.* 12, 135-143, 1993.
22. Tamura, K., Kanaoka, Y., Jinno, S., Nagata, A., Ogiso, Y., Shimizu, K., Hayakawa, T., Nojima, H., and Okayama, H. Cyclin G: A new mammalian cyclin with a potential tyrosine phosphorylation site. *Oncogene* 8, 2113-2118, 1993.
23. Jinno, S., Suto, K., Nagata, A., Igarashi, M., Kanaoka, Y., Nojima, H., and Okayama, H. *Cdc25A* is a novel phosphatase functioning early in the cell cycle. *EMBO J.* 13, 1549-1556, 1994.
24. Sugiyama, A., Tanaka, K., Okazaki, K., Nojima, H., and Okayama, H. A zinc finger protein controls the onset of premeiotic DNA synthesis of fission yeast in a *Mei2*-independent cascade. *EMBO J.* 13, 1881-1887, 1994.
25. Miyamoto, M., Tanaka, K., and Okayama, H. *res2+*, a new member of *cdc10+/SWI4* family, controls the  $\infty$ start $\infty$ h of mitotic and meiotic cycles in fission yeast. *EMBO J.* 13, 1873-1880, 1994.
26. Obara-Ishihara, T., and Okayama, H. A B-type cyclin regulates conjugation via interaction with cell cycle "start" genes in fission yeast. *EMBO J.* 13, 1863-1872, 1994.
27. Murakami, H., and Okayama, H. A kinase from fission yeast responsible for blocking mitosis in S phase. *Nature* 374, 817-819, 1995.
28. Terada, Y., Tatsuka, M., Jinno, S., and Okayama, H. Requirement for tyrosine phosphorylation of Cdk4 in G1 arrest induced by ultraviolet irradiation. *Nature* 367, 358-362, 1995.
29. Nakashima, N., Tanaka, K., Sturm, S., and Okayama, H. Fission Yeast Rep2 is a putative transcriptional activator subunit for the cell cycle "start" function of *Res2-Cdc10*. *EMBO J.* 14, 4794-4802, 1995.
30. Okayama, H., Nagata, A., Jinno, S., Murakami, H., Tanaka, K., and Nakashima, N. Cell cycle control in fission yeast and mammals identification of new regulatory mechanisms. 1996, *Adv. Cancer Re.* 69, 17-62.
31. Kato, Jr., T., Okazaki, K., Murakami, H., Stettler, S., Fantes, A., P., and Okayama, H. Stress signal, mediated by a Hog1-like MAP kinase, controls sexual development in fission yeast. *FEBS Let.* 378, 207-212, 1996.
32. Kizaka-Kondoh, S., Matsuda, M., and Okayama, H. CrkII signals from epidermal growth factor receptor to Ras. *Proc. Natl. Acad. Sci. USA* 93, 12177-12182, 1996.
33. Yamaguchi, S., Murakami, H., and Okayama, H. A WD repeat protein controls the cell cycle and differentiation by negatively regulating Cdc2/B-type cyclin complexes. *Mol. Biol. Cell* 8, 2475-2486, 1997.
34. Okazaki, N., Okazaki, K., Watanabe, Y., Kato-Hayashi, M., Yamamoto, M., and Okayama, H. Novel factor highly conserved among eukaryotes controls sexual development in fission yeast. *Mol. Cell. Biol.* 18, 887-895, 1998.
35. Tahara, S., Tanaka, K., Yuasa, Y., and Okayama, H. Functional domains of Rep2, a transcriptional activator subunit for *Res2-Cdc10*, controlling the cell cycle start. *Mol. Biol. Cell* 9, 1577-1588, 1998.
36. Tsukahara, K., Yamamoto, H., and Okayama, H. An RNA binding protein negatively controlling differen-

- tiation in fission yeast. *Mol Cell. Biol.* 18, 4488-4498, 1998.
37. Jinno, S., Hung, S.-C., and Okayama, H. Cell cycle start from quiescence controlled by tyrosine phosphorylation of Cdk4. *Oncogene* 18, 565-577, 1999.
  38. Yamamoto, H., Tsukahara, K., Kanaoka, Y., Jinno, S., and Okayama, H. Isolation of a mammalian homologue of a fission yeast differentiation regulator. *Mol. Cell. Biol.* 19, 3829-3841, 1999.
  39. Jinno, S., Hung, S.-C., Yamamoto, Y., Lin, J., Nagata, A., and Okayama, H. Oncogenic stimulation recruits Cdk6 in the cell cycle start in rat fibroblast. *Proc. Natl. Acad. Sci. USA* 96, 13197-13202, 1999.
  40. Suto, K., Murakami, H., Nagata, A., and Okayama, H. A double-strand Break repair component is essential for S phase completion in fission yeast cell cycling. *Mol. Biol. Cell* 10, 3331-3343, 1999.
  41. Masuda, M., Nagai, Y., Oshima, N., Tanaka, K., Murakami, H., Igarashi, H., and Okayama H. Genetic Studies with the Fission Yeast *Schizosaccharomyces pombe* Suggest Involvement of Wee1, Ppa2, and Rad24 in Induction of Cell Cycle Arrest by Human Immunodeficiency Virus Type 1 Vpr. *J. Virol.* 74, 2636-2646, 2000.
  42. Tanaka, K., Yonekawa, T., Kawasaki, Y., Kai, M., Furuya, K., Iwasaki, M., Murakami, H., Yanagida, M., and Okayama, H. Fission yeast Eso1p is required for establishing chromatid cohesion during S phase. *Mol. Cell. Biol.* 20, 3459-3469, 2000.
  43. Yamaguchi, S., Okayama, H. and Nurse, P. Fission yeast Fizzy-related protein *Srw1p* is a G(1)-specific promoter of mitotic cyclin B degradation. *EMBO J.* 19, 3968-3977, 2000.
  44. Tanaka, K., and Okayama, H. A Pcl-like cyclin activates the *Res2p-Cdc10p* cell cycle 'start' transcriptional factor in fission yeast. *Mol. Biol. Cell* 11, 2845-2862, 2000.
  45. Nakamura, E., Isobe, H., Tomita, N., Sawamura, M., Jinno, S., and Okayama, H. Functionalized fullerene as an artificial vector for transfection. *Angew. Chem.* 112, 4424-4427, 2000.
  46. Jinno, S., Lin, J., Yageta, M., and Okayama, H. Oncogenic cell cycle start control. *Mut. Res.* 477, 23-29, 2001.
  47. Lin, J., Jinno, S., and Okayama H. Cyclin D3-Cdk6 complex evades inhibition by inhibitor proteins and uniquely controls cell's growth competence. *Oncogene* 20, 2000-2009, 2001.
  48. Tanaka, K., Hao, Z., Kai, M. and Okayama, H. Establishment and maintenance of sister chromatid cohesion in fission yeast by a unique mechanism. *EMBO J.* 20, 5779-5790, 2001.
  49. Jinno, S., Yageta, M., Nagata, A. and Okayama, H. *Cdc6* requires anchorage for its expression. *Oncogene* 21, 1777-1784, 2002.
  50. Hiroi, N., Jinno, S., and Okayama, H. Mammalian *Rcd1* is a novel transcriptional cofactor that mediates retinoic acid-induced cell differentiation. *EMBO J.* 21, 5235-5244, 2002.



# Department of Cellular Signaling

## Outline and Research Objectives

When cells are stimulated, by the serial actions of various enzymes, biologically active lipid molecules are produced and released. They include prostaglandins, leukotrienes, platelet-activating factor (PAF), lysophosphatidic acid (LPA) etc., collectively termed lipid mediators (Fig 1). In concert with various neurotransmitters and hormones, these lipid mediators are playing important roles in self-defenses and maintenance of homeostasis. Unlike the biogenic amines or peptide mediators, lipid mediators are not stored in granules, but they are biosynthesized from precursor lipids when necessary. To elucidate the functions of lipid mediators, we isolated enzymes involved in the biosyntheses and metabolism of lipid mediators, isolated G-protein-coupled receptors, and identification of intracellular signaling. We are especially interested in identifying the specific roles of lipid mediators in inflammatory responses as well as neuronal functions. We generated several transgenic or knockout mice and analysed their roles in vivo. By mass spectrometric analyses, we also measured dynamic changes in membrane lipid compositions, the significance of these changes being in general signaling pathway. In the postsequence of whole human genome, the intensive studies of protein regulation as well as behavior of small lipid metabolites are of the highest importance.


## Faculties and Students

Professor	Takao Shimizu, M.D., Ph.D. (1991-)
Associate Professor	Takehiko Yokomizo, M.D., Ph.D.
Associate	.....3
Postdoctoral Fellows	.....4
Graduate Students	.....12
Research Students	.....7
Secretary	.....2

enzymes involved in the biosyntheses and metabolism of lipid mediators. Leukotriene A4 hydrolase, one of the key enzyme in the biosynthesis of chemotactic leukotrienes, was cloned and characterized in our laboratory. This achievement was the first successful example of molecular cloning of the enzymes in the field of lipid mediators. We also obtained PAF receptor, as the first successful example of receptor cloning of lipid mediators, followed by cloning receptors of various lipid mediators. We determined the regulation of these enzymes by Ca-dependent intracellular translocation, phosphorylation by various kinases, and other posttranslational modifications. We also

## Past Research and Major Accomplishments

We have purified and cDNA cloned various




generated PAF receptor-overexpressing mice, PAF receptor-deficient mice, leukotriene receptor-deficient mice, and the mice deficient in cytosolic phospholipase A2 (cPLA2), which are involved in the syntheses of eicosanoids and PAF. By analyzing the phenotypes of these mice, we reported that the mediators are involved in the pathogenesis of various inflammatory and immune disorders, as well as normal physiology including reproduction and synaptic plasticity. Independently, one of the Associate is working on axon guidance molecules, by establishing knockout mice of guidance molecules (Sema 3A), and analyses of their multiple phenotypes.

## Current Research

Followings are ongoing projects in our laboratory.

1. Elucidation of enzymes in the biosyntheses of lipid mediators, their regulation and mechanism of intracellular translocation by stimuli.
2. Deorphaning projects of putative lipid mediator GPCRs, which include indentificaion of novel lipid mediators (Fig. 2).
3. Elucidation of GPCR-sorting mechanism in polarized cells (kidney epithelial cells, neuron etc.)
4. Phenotype analyses of various genetic engineered mice. Understanding of the molecular mechanism of individual phenotypes in depth.

## Phylogenetic Tree of various GPCRs



5. Establishment of novel gene-targeted mice (enzymes and receptors), and their congenic line (B6, Balb/c, DBA etc.)
6. Identification of Sema3A knockout mice, in nervous systems, olfactory systems, bone formation.

### Future Prospects

We will pursue following different projects, lead by each faculty member.

1. Identification of the roles of lipid mediators in the central nervous system. For this purpose, we will analyze the localization and subcellular localization of enzymes involved in the biosyntheses of lipid mediators. It is the most important to determine, how and which direction (either axon or dendrite), these enzyme cause translocation in a stimulus-dependent manner. The mice deficient of enzymes or receptors of lipid mediators are useful to identify the roles of mediators in the central nervous systems. Some link has been reported between Sema3A axon guidance molecules and lipid mediators. By the use of double knockout mice (Sema3A and lipid mediators), more confirmative and direct evidence will be obtained.
2. We have so far obtained various phenotypes of genetic engineered mice, but molecular mechanisms underlying these phenotypes remain mostly unknown. The link between lipid mediators and hormones, neurotransmitters, and cytokines will be analyzed to obtain a whole view.
3. By mass spectrometric analyses, we like to find out the temporal and positional dynamic changes of membrane compositions including Raft and caveolae. Also, mass spectrometry attached with HPLC will aid in the identification of novel natural lipid mediators (deorphaning project). For these purposes, we recently built a new research group called Department of Lipid Metabolome, by donation. We have collected several excellent lipid biochemists, and mass spectrometer specialists. Metabolome (metabolomics) is a new research strategy after genome and proteome research. The study is to analyze in detail small-sized molecules (metabolites), and in combination with proteomics, we will gain a more broad view how cells adapt to a new environment, change membrane fluidity, and cause metabolic changes, which finally yield to gene expression.

### Research Grants

1. 1998-2003 CREST of Japan Science and Technology Corporation
2. 2001-2004 PREST of Japan Science and Technology Corporation

3. 1999-2002 Grant from the Ministry of Education, Science, Culture, Sports, and Technology of Japan (A, B, and C)
4. 1997 Priority Area A, from the Ministry of Education, Science, Culture, Sports, and Technology of Japan.
5. 1996-2000 Ministry of Welfare, Health and Labor.


### Select Publications (50 among 128 publications between 1991 and 2002)

1. Ito, N., Yokomizo, T., Sasaki, T., Kurosu, H., Penninger, J., Kanaho, Y., Katada, T., Hanaoka, K., and Shimizu, T. Requirement of phosphatidylinositol 3-kinase-activation and Ca influx for leukotriene B<sub>4</sub>-induced enzyme release. *J. Biol. Chem.* in press, 2002.
2. Stromgaard, K., Saito, D.R., Shindou, H., Ishii, S., Shimizu, T., and Nakanishi, K. Ginkgolide derivatives for photolabeling studies: preparation and pharmacological evaluation. *J. Med. Chem.* 45,4038-46, 2002.
3. Wong, D.A., Uozumi, N., Kita, Y., and Shimizu, T. Discrete role for cytosolic phospholipase A<sub>2</sub>-alpha in platelets: Studies using single and double mutant mice of cytosolic and group IIA-secretory phospholipase A<sub>2</sub>. *J. Exp. Med.* 196,349-57, 2002.
4. Ogasawara, H., Ishii, S., Yokomizo, T., Kakinuma, T., Komine, M., Tamaki, K., Shimizu, T., and Izumi, T. Characterization of mouse cysteinyl leukotriene receptors, mCysLT1 and mCysLT2: Differential pharmacological properties and tissue distribution. *J. Biol. Chem.* 277, 18763-18768, 2002.
5. Nagase, T., Uozumi, N., Ishii, S., Kita, Y., Yamamoto, H., Ohga, E., Ouchi, Y. and Shimizu, T. A pivotal role of cytosolic phospholipase A<sub>2</sub> in bleomycin-induced pulmonary fibrosis. *Nature Med.* 8, 480-484, 2002.
6. Ohshima, N., Ishii, S., Izumi, T., and Shimizu, T. Receptor-dependent metabolism of platelet-activating factor in murine macrophages. *J. Biol. Chem.* 277, 9722-9727, 2002.
7. Nagase, T., Ishii, S., Shindou, H., Ouchi, Y., and Shimizu, T. Airway hyperresponsiveness in transgenic mice overexpressing platelet activating factor receptor is mediated by an atropine-sensitive pathway. *Am. J. Respir. Crit. Care Med.* 165, 200-205, 2002.
8. Yokomizo, T., Izumi, T., and Shimizu, T. Leukotriene B<sub>4</sub>: metabolism and signal transduction. *Arch. Biochem. Biophys.* 385, 231-241, 2001.
9. Yokomizo, T., Kato, K., Hagiya, H., Izumi, T., and Shimizu, T. Hydroxyeicosanoids bind to and activate the low affinity leukotriene B<sub>4</sub> receptor, BLT<sub>2</sub>. *J. Biol. Chem.* 276, 12454-12459, 2001.
10. Wu, C., Stojanov, T., Chami, O., Ishii, S., Shimizu, T., Li, A., and O'Neill, C. Evidence for the autocrine induction of capacitation of mammalian spermatozoa. *J. Biol. Chem.* 276, 26962-26968, 2001.
11. Yamashita, A., Kawagishi, N., Miyashita, T., Nagatsuka, T., Sugiura, T., Kume, K., Shimizu, T.,

- and Waku, K. ATP-independent fatty acyl-coenzyme A synthesis from phospholipid: coenzyme A-dependent transacylation activity toward lysophosphatidic acid catalyzed by acyl-coenzyme A:lysophosphatidic acid acyltransferase. *J. Biol. Chem.* 276, 26745-26752, 2001.
12. Kim, Y. J., Noguchi, S., Hayashi, Y. K., Tsukahara, T., Shimizu, T., and Arahata, K. The product of an oculopharyngeal muscular dystrophy gene, poly(A)-binding protein 2, interacts with SKIP and stimulates muscle-specific gene expression. *Hum. Mol. Genet.* 10, 1129-1139, 2001.
  13. Fukunaga, K., Ishii, S., Asano, K., Yokomizo, T., Shiomi, T., Shimizu, T., and Yamaguchi, K. Single nucleotide polymorphism of human platelet-activating factor receptor impairs G-protein activation. *J. Biol. Chem.* 276, 43025-43030, 2001.
  14. Aihara, M., Ishii, S., Kume, K., and Shimizu, T. Interaction between neurone and microglia mediated by platelet-activating factor. *Genes Cells* 5, 397-406, 2000.
  15. Noiri, E., Yokomizo, T., Nakao, A., Izumi, T., Fujita, T., Kimura, S., and Shimizu, T. An in vivo approach showing the chemotactic activity of leukotriene B(4) in acute renal ischemic-reperfusion injury. *Proc. Natl. Acad. Sci. USA* 97, 823-828, 2000.
  16. Nagase, T., Uozumi, N., Ishii, S., Kume, K., Izumi, T., Ouchi, Y., and Shimizu, T. Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2. *Nat. Immunol.* 1, 42-46, 2000.
  17. Kato, K., Yokomizo, T., Izumi, T., and Shimizu, T. Cell-specific transcriptional regulation of human leukotriene B(4) receptor gene. *J. Exp. Med.* 192, 413-420, 2000.
  18. Yokomizo, T., Kato, K., Terawaki, K., Izumi, T., and Shimizu, T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. *J. Exp. Med.* 192, 421-432, 2000.
  19. Takaku, K., Sonoshita, M., Sasaki, N., Uozumi, N., Doi, Y., Shimizu, T., and Taketo, M. M. Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. *J. Biol. Chem.* 275, 34013-34016, 2000.
  20. Nakatani, N., Uozumi, N., Kume, K., Murakami, M., Kudo, I., and Shimizu, T. Role of cytosolic phospholipase A2 in the production of lipid mediators and histamine release in mouse bone-marrow-derived mast cells. *Biochem. J.* 352 Pt 2, 311-317, 2000.
  21. Okamoto, H., Takuwa, N., Yokomizo, T., Sugimoto, N., Sakurada, S., Shigematsu, H., and Takuwa, Y. Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3. *Mol. Cell Biol.* 20, 9247-9261, 2000.
  22. Kobayashi, K., Ishii, S., Kume, K., Takahashi, T., Shimizu, T., and Manabe, T. Platelet-activating factor receptor is not required for long-term potentiation in the hippocampal CA1 region. *Eur. J. Neurosci.* 11, 1313-1316, 1999.
  23. Nagase, T., Ishii, S., Kume, K., Uozumi, N., Izumi, T., Ouchi, Y., and Shimizu, T. Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice. *J. Clin. Invest.* 104, 1071-1076, 1999.
  24. Hirabayashi, T., Kume, K., Hirose, K., Yokomizo, T., Iino, M., Itoh, H., and Shimizu, T. Critical duration of intracellular Ca<sup>2+</sup> response required for continuous translocation and activation of cytosolic phospholipase A2. *J. Biol. Chem.* 274, 5163-5169, 1999.
  25. Ishii, I., Saito, E., Izumi, T., Ui, M., and Shimizu, T. Agonist-induced sequestration, recycling, and resensitization of platelet-activating factor receptor. Role of cytoplasmic tail phosphorylation in each process. *J. Biol. Chem.* 273, 9878-9885, 1998.
  26. Hoshino, M., Izumi, T., and Shimizu, T. Leukotriene D4 activates mitogen-activated protein kinase through a protein kinase C $\alpha$ -Raf-1-dependent pathway in human monocytic leukemia THP-1 cells. *J. Biol. Chem.* 273, 4878-4882, 1998.
  27. Ishii, S., Kuwaki, T., Nagase, T., Maki, K., Tashiro, F., Sunaga, S., Cao, W. H., Kume, K., Fukuchi, Y., Ikuta, K., Miyazaki, J., Kumada, M., and Shimizu, T. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. *J. Exp. Med.* 187, 1779-1788, 1998.
  28. Hirohashi, T., Suzuki, H., Ito, K., Ogawa, K., Kume, K., Shimizu, T., and Sugiyama, Y. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats. *Mol. Pharmacol.* 53, 1068-1075, 1998.
  29. Ishii, S., Nagase, T., Tashiro, F., Ikuta, K., Sato, S., Waga, I., Kume, K., Miyazaki, J., and Shimizu, T. Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. *EMBO J.* 16, 133-142, 1997.
  30. Kume, K., and Shimizu, T. Platelet-activating factor (PAF) induces growth stimulation, inhibition, and suppression of oncogenic transformation in NRK cells overexpressing the PAF receptor. *J. Biol. Chem.* 272, 22898-22904, 1997.
  31. Ishii, I., Izumi, T., Tsukamoto, H., Umeyama, H., Ui, M., and Shimizu, T. Alanine exchanges of polar amino acids in the transmembrane domains of a platelet-activating factor receptor generate both constitutively active and inactive mutants. *J. Biol. Chem.* 272, 7846-7854, 1997.
  32. Honda, Z., Suzuki, T., Hirose, N., Aihara, M., Shimizu, T., Nada, S., Okada, M., Ra, C., Morita, Y., and Ito, K. Roles of C-terminal Src kinase in the initiation and the termination of the high affinity IgE receptor-mediated signaling. *J. Biol. Chem.* 272, 25753-25760, 1997.
  33. Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y., and Shimizu, T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. *Nature* 387, 620-624, 1997.



34. Uozumi, N., Kume, K., Nagase, T., Nakatani, N., Ishii, S., Tashiro, F., Komagata, Y., Maki, K., Ikuta, K., Ouchi, Y., Miyazaki, J., and Shimizu, T. Role of cytosolic phospholipase A2 in allergic response and parturition. *Nature* 390, 618-622, 1997.
35. Yokomizo, T., Ogawa, Y., Uozumi, N., Kume, K., Izumi, T., and Shimizu, T. cDNA cloning, expression, and mutagenesis study of leukotriene B4 12-hydroxydehydrogenase. *J. Biol. Chem.* 271, 2844-2850, 1996.
36. Ferby, I. M., Waga, I., Hoshino, M., Kume, K., and Shimizu, T. Wortmannin inhibits mitogen-activated protein kinase activation by platelet-activating factor through a mechanism independent of p85/p110-type phosphatidylinositol 3-kinase. *J. Biol. Chem.* 271, 11684-11688, 1996.
37. Kishimoto, S., Shimadzu, W., Izumi, T., Shimizu, T., Fukuda, T., Makino, S., Sugiura, T., and Waku, K. Regulation by IL-5 of expression of functional platelet-activating factor receptors on human eosinophils. *J. Immunol.* 157, 4126-4132, 1996.
38. Mori, M., Aihara, M., Kume, K., Hamanoue, M., Kohsaka, S., and Shimizu, T. Predominant expression of platelet-activating factor receptor in the rat brain microglia. *J. Neurosci.* 16, 3590-3600, 1996.
39. Mutoh, H., Fukuda, T., Kitamaoto, T., Masushige, S., Sasaki, H., Shimizu, T., and Kato, S. Tissue-specific response of the human platelet-activating factor receptor gene to retinoic acid and thyroid hormone by alternative promoter usage. *Proc. Natl. Acad. Sci. USA* 93, 774-779, 1996.
40. Watanabe, T., Waga, I., Honda, Z., Kurokawa, K., and Shimizu, T. Prostaglandin F2 alpha stimulates formation of p21ras-GTP complex and mitogen-activated protein kinase in NIH-3T3 cells via Gq-protein-coupled pathway. *J. Biol. Chem.* 270, 8984-8990, 1995.
41. Honda, Z., Takano, T., Hirose, N., Suzuki, T., Muto, A., Kume, S., Mikoshiba, K., Itoh, K., and Shimizu, T. Gq pathway desensitizes chemotactic receptor-induced calcium signaling via inositol trisphosphate receptor down-regulation. *J. Biol. Chem.* 270, 4840-4844, 1995.
42. Shirasaki, H., Nishikawa, M., Adcock, I. M., Mak, J. C., Sakamoto, T., Shimizu, T., and Barnes, P. J. Expression of platelet-activating factor receptor mRNA in human and guinea pig lung. *Am. J. Respir. Cell Mol. Biol.* 10, 533-537, 1994.
43. Takano, T., Honda, Z., Sakanaka, C., Izumi, T., Kameyama, K., Haga, K., Haga, T., Kurokawa, K., and Shimizu, T. Role of cytoplasmic tail phosphorylation sites of platelet-activating factor receptor in agonist-induced desensitization. *J. Biol. Chem.* 269, 22453-22458, 1994.
44. Honda, Z., Takano, T., Gotoh, Y., Nishida, E., Ito, K., and Shimizu, T. Transfected platelet-activating factor receptor activates mitogen-activated protein (MAP) kinase and MAP kinase kinase in Chinese hamster ovary cells. *J. Biol. Chem.* 269, 2307-2315, 1994.
45. Ferby, I. M., Waga, I., Sakanaka, C., Kume, K., and Shimizu, T. Wortmannin inhibits mitogen-activated protein kinase activation induced by platelet-activating factor in guinea pig neutrophils. *J. Biol. Chem.* 269, 30485-30488, 1994.
46. Bito, H., Mori, M., Sakanaka, C., Takano, T., Honda, Z., Gotoh, Y., Nishida, E., and Shimizu, T. Functional coupling of SSTR4, a major hippocampal somatostatin receptor, to adenylate cyclase inhibition, arachidonate release and activation of the mitogen-activated protein kinase cascade. *J. Biol. Chem.* 269, 12722-12730, 1994.
47. Bito, H., Nakamura, M., Honda, Z., Izumi, T., Iwatsubo, T., Seyama, Y., Ogura, A., Kudo, Y., and Shimizu, T. Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca<sup>2+</sup> in hippocampal neurons. *Neuron* 9, 285-294, 1992.
48. Nakamura, M., Honda, Z., Izumi, T., Sakanaka, C., Mutoh, H., Minami, M., Bito, H., Seyama, Y., Matsumoto, T., Noma, M., and Shimizu, T. Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. *J. Biol. Chem.* 266, 20400-20405, 1991.
49. Honda, Z., Nakamura, M., Miki, I., Minami, M., Watanabe, T., Seyama, Y., Okado, H., Toh, H., Ito, K., Miyamoto, T., and Shimizu, T. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. *Nature* 349, 342-346, 1991.
50. Watanabe, T., Yatomi, Y., Sunaga, S., Miki, I., Ishii, A., Nakao, A., Higashihara, M., Seyama, Y., Ogura, M., Saito, H., Kurokawa, K., and Shimizu, T. Characterization of prostaglandin and thromboxane receptors expressed on a megakaryoblastic leukemia cell line, MEG-01s. *Blood* 78, 2328-2336, 1991.



# Department of Physiological Chemistry and Metabolism

## Outline and Research Objectives

The Department of Physiological Chemistry and Nutrition, the predecessor of the present department, was founded in 1952. The successive professors were as follows;

The first professor: Haruhisa Yoshikawa (1952~1969)

The second professor: Osamu Hayaishi (1970~1974)

The third professor: Yoshitake Mano (1974~1982)

The fourth professor: Yousuke Seyama (1983~2001)

During the past 50 years, these professors lead high-quality researches in the field of biochemistry, metabolism and nutrition and greatly contributed to scientific progresses in Japan. Upon the restructuring of the university system in 1997, the department was renamed 'Department of Physiological Chemistry and Metabolism' as one unit of the Specialty of Molecular Cell Biology. In 2002, Dr. Hiroki Kurihara was designated as a successor of Professor Yousuke Seyama, and started new researches on developmental biology and technology as well as regenerative medicine.

## Faculties and Students

Professor and Chair	Hiroki Kurihara, M.D., Ph.D. (2002~)
Associate .....	3
Postdoctoral Fellow .....	1
Graduate Student.....	2
Secretary .....	1

## Past Research and Major Accomplishments

### 1. Vascular Biology

#### (1) Biology of Vasoactive Peptides

##### i) Endothelin

###### a. Discovery and Basic Characterization of Endothelin

Our researches started with contribution to the discovery of endothelin (ET-1), an endothelium-derived vasoactive peptide, with Drs. Masashi Yanagisawa, Tomoh Masaki and colleagues in 1987. Then, we studied the role of ET-1 in vascular physiology and pathophysiology and revealed its vasoconstrictive effect on *in vivo* canine coronary arteries and induction of the ET-1 gene by some cytokines and flow-induced mechanical stress in vascular endothelial cells.

###### b. Endothelin-1 Knockout Mice

In 1991, we introduced the technique of gene targeting in mice to our lab to further analyze the biological implication of ET-1. As a result, we found two novel and important roles of ET-1. First, ET-1 proved to lower blood pressure when it acts

in the central nervous system although it mainly acts as a pressor in the periphery. ET-1 also modulates stress responses in the central nervous system by regulating catecholamine metabolism. Second, ET-1 proved to be essential for embryogenesis. The phenotype of mice lacking ET-1 involved craniofacial and cardiac neural crest-derived structures including the branchial arches and great vessels. Indeed, ET-1 was the first vasoactive substance bound to G protein-coupled receptors that proved to be involved in embryonic development (See 2-1)).

###### c. Endothelin-1 Overexpressing Mice

We found that the expression of ET-1 and its processing enzyme ECE-1 is increased in the lesion of human atherosclerosis and experimental vascular injury. The effect of overexpressed ET-1 was further analyzed in transgenic mice and proved to cause mesangial hyperplasia and glomerulosclerosis in the kidney. This result was indicative of the stimulating effect of ET-1 on cellular proliferation and remodeling *in vivo*.

##### ii) Adrenomedullin

###### a. Adrenomedullin Overexpressing Mice

Adrenomedullin (AM), a vasodilating peptide, can be regarded as a counterpart of ET-1 in vascular tone regulation. We investigated the *in vivo* effect of AM by producing transgenic mice overexpressing AM and found NO-dependent hypotension and resistance to endotoxin shock (decrease in lethality) in transgenic mice. These results suggested that AM may lower blood pressure by stim-

ulating NO production and that AM may protect tissues and organs from shock-induced damage.

### **b. Adrenomedullin Knockout Mice**

The biological importance of AM was further investigated by gene targeting. We demonstrated that AM is indispensable for the vascular morphogenesis during embryonic development and for postnatal regulation of blood pressure by stimulating NO production, confirming the hypothesis derived from AM overexpression mice.

### **iii) CGRP**

CGRP is structural related to AM and shares the common receptor CRLR. To investigate systematically the differential role of the AM/CGRP family members, we established alphaCGRP knockout mice. The resultant phenotype revealed that alphaCGRP contributes to the regulation of cardiovascular function through inhibitory modulation of sympathetic nervous activity and that AM and CGRP have distinct physiological roles.

### **(2) Transgenic techniques**

During gene manipulation studies in mice, we found that the ET-1 gene promoter is useful for vessel-selective gene expression. This promoter was used not only to overexpress ET-1 and AM but also to make endothelial NO synthase and 15-lipoxygenase overexpressing mice by our collaborators with fruitful results. Recently, we realized targeting gene expression in vascular smooth muscle cells by using the ET-A receptor (ETAR) gene promoter.

## **2. Developmental Biology**

### **(1) Neural Crest Development**

Craniofacial and cardiovascular defects in ET-1 knockout embryos gave a clue to the elucidation of mechanisms for branchial arch formation contributed by neural crest cells. By subsequent analysis, we revealed that ET-1 regulates several downstream genes such as HAND1/2 and Gooseoid transcription factors to contribute to cranial/cardiac neural crest development. Recently, we established ETAR promoter::GFP and ETAR promoter::TVA (avian retrovirus receptor) to visualize and isolate ETAR+ neural crest cells and to transfer genes specifically to them via retroviral vectors. These systems serve as very useful tools for the analysis of neural crest-derived branchial arch development.

### **(2) Vascular Development**

ET-1 knockout mice also demonstrated defects in the great vessels and cardiac outflow tract, to which cardiac neural crest cells largely contribute. From this result, we found that ET-1 is important in vascular smooth muscle cell development originated from neu-

ral crest cells and that the ET-1 to HAND2 signaling pathway seems to be critical. The outcome from AM knockout mice showed that AM is important in the formation of basement membrane during angiogenesis to stabilize vascular network.

## **3. Collaborative Works**

### **(1) Biology of Metalloproteinase**

In collaboration with Dr. Kouji Matsushima (Dept. of Molecular Preventive Medicine), we exploited the biological implication of ADAMTS-1, a member of the ADAM-type metalloproteinase family, by gene targeting. We found that ADAMTS-1 is important for normal growth, fertility and organ development (the kidneys, adrenal glands, adipose tissues etc.).

### **(2) Biology of Antimicrobial Peptides**

In collaboration with Drs. Yasuyoshi Ouchi and Takahide Nagase (Dept. of Geriatrics), we are studying about defensins, endogenous antimicrobial peptides. We have identified several novel types of human and mouse beta-defensins which are expressed skeletal muscle and epididymis.

## **Current Research**

### **1. Vascular Biology**

We have converged our previous achievement of vascular biology on the aspect of developmental biology including vascular development as described below.

## **2. Developmental Biology**

### **(1) Neural Crest Development**

Extending our achievement of ET-1 knockout mice, we are studying the mechanism how the intercellular and intracellular signaling system related ET-1 is involved in neural crest development and branchial arch formation because it may give a clue to the insight how signaling interactions can change cellular behavior to lead to morphogenesis. For this purpose, we have established GFP and TVA transgenic mice as described and are now establishing some other mice which will be useful for the analysis of branchial arch formation. We are also performing a systematic screening for differential gene expression by DNA microarray followed by in situ hybridization. By this method, several important genes are to be obtained.

We are also studying about neural crest differentiation using murine neural crest cell culture and Sendai virus vectors developed by Drs. Yoshiyuki Nagai and Atsushi Kato. In our preliminary result, we realized nearly 100 % gene transfer into neural crest cells and are analyzing the effect of some genes on neural crest

differentiation. Using some markers, we are also trying to isolate neural crest stem cells.

We are further looking for the mechanism how some transcription factors important for neural crest development can exert their effects. For this purpose, we are performing yeast two-hybrid screening using Pax3 and HAND2 as baits. We have obtained several interesting clones and are analyzing their molecular characteristics.

## (2) Vascular Development

Above-mentioned studies concerning neural crest differentiation include the issue of vascular smooth muscle cell differentiation and we are trying to identify the target genes of the ET-1-HAND2 pathway that is important for smooth muscle differentiation. Two-hybrid studies also involve this theme. Abnormalities in vascular formation in AM knockout mice are also being investigated further concerning the mechanism.

In addition, we have started studies on vascular endothelial cell differentiation using the embryonic stem cell system and are looking for possible interaction between neural crest-derived smooth muscle precursors and endothelial precursors. It may clarify a novel cellular interaction mechanism which can stimulate vascular formation.

## 3. Collaborative Works

In collaboration with Drs. Yasuyoshi Ouchi and Takahide Nagase (Dept. of Geriatrics), we are starting further study on defensins using gene manipulation in mice.

## Future Prospects

### (1) Basic research

Our future study will focus mainly on neural crest and vascular development. Especially, major questions are (1) how do intracellular mechanisms modulate stem cell behavior including fate determination and differentiation, and (2) how are cell behaviors integrated into morphogenesis and organogenesis. By studying neural crest development as a model, we expect that we can approach these general issues. For our coming research, we are introducing some new techniques such as nuclear transfer.

### (2) Applied research

Our current researches on vascular development using embryonic stem cells are close to applied researches in the field of regenerative medicine. On this background together with nuclear transfer technique, we are planning translational researches to generate vessels and other tissues and organs related

neural crest cells.

## Research Grants

1. JSPS (Japan Society for the Promotion of Science) Research for the Future Program (2000.4~2004.3) total 240,000,000 yen.
2. Grants-in-Aid for Scientific Research from JSPS, Scientific Research (B) (2002.4~2004.3) total 14,900,000 yen
3. Grants-in-Aid for Scientific Research from JSPS, Exploratory Research (C) (2002.4~2004.3) total 9,900,000 yen
4. Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Culture, Japan, Priority Areas Research (A), Allotted. (2000.4~2001.3) total 1,800,000 yen.
5. the Research Grant for Cardiovascular Diseases (14C-1) from the Ministry of Health and Welfare (2002.4~2005.3) total 6,300,000 yen.

## Select Publications

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 332: 411-415, 1988.
2. Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. *FEBS Lett.* 238: 249-252, 1988.
3. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Hamaoki M, Kato H, Yazaki Y. Transforming growth factor- $\beta$  stimulates the expression of endothelin mRNA by vascular endothelial cells. *Biochem. Biophys. Res. Commun.* 359: 1435-1440, 1989.
4. Kurihara H, Yoshizumi M, Sugiyama T, Yamaoki K, Nagai R, Takaku F, Satoh H, Inui J, Yanagisawa M, Masaki T, Yazaki Y. The possible role of endothelin-1 in the pathogenesis of coronary vasospasm. *J. Cardiovasc. Pharmacol.* 13(Suppl. 5): S132-S137, 1989.
5. Kurihara H, Yamaoki K, Nagai R, Yoshizumi M, Takaku F, Satoh H, Inui J, Yazaki Y. Endothelin: a potent vasoconstrictor associated with coronary vasospasm. *Life Sci.* 44: 1937-1943, 1989.
6. Goto K, Kasuya Y, Matsuki N, Takuwa Y, Kurihara H, Ishikawa T, Kimura S, Yanagisawa M, Masaki T. Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca<sup>2+</sup>-channel in vascular smooth muscle. *Proc. Natl. Acad. Sci. U.S.A.* 86: 3915-3918, 1989.
7. Ouchi Y, Kim S, Souza AC, Iijima S, Hattori A, Orimo H, Yoshizumi M, Kurihara H, Yazaki Y. Central effect of endothelin on blood pressure in conscious rats. *Am J. Physiol.* 256: H1747-H1751, 1989.
8. Yoshizumi M, Kurihara H, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Yazaki Y. Hemodynamic

- shear stress stimulates endothelin production by cultured endothelial cells. *Biochem. Biophys. Res Commun.* 161: 859-864, 1989.
9. Yoshizumi M, Kurihara H, Morita T, Yamashita T, Oh-hashii Y, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Yazaki Y. Interleukin-1 induces the production of endothelin-1 by cultured endothelial cells. *Biochem. Biophys. Res. Commun.* 166: 324-329, 1990.
  10. Morita T, Kurihara H, Yoshizumi M, Maemura K, Sugiyama T, Nagai R, Yazaki Y. Polymorphonuclear leukocytes have dual effects on endothelin-1: the induction of endothelin-1 mRNA expression in vascular endothelial cells and modification of the endothelin-1 molecule. *Heart Vessels* 8: 1-6, 1993.
  11. Morita T, Kurihara H, Maemura K, Yoshizumi M, Yazaki Y. Disruption of cytoskeletal structures mediates shear stress-induced endothelin-1 gene expression in cultured porcine aortic endothelial cells. *J. Clin. Invest.* 92: 1706-1712, 1993.
  12. Morita T, Yoshizumi M, Kurihara H, Maemura K, Nagai R, Yazaki Y. Shear stress increases heparin-binding epidermal growth factor-like growth factor mRNA levels in human vascular endothelial cells. *Biochem. Biophys. Res. Commun.* 197: 256-262, 1993.
  13. Kurihara Y\*, Kurihara H\*, Suzuki H, Kodama T, Maemura K, Nagai R, Oda H, Kuwaki T, Cao W-H, Kamada N, Jishage K, Ouchi Y, Azuma S, Toyoda Y, Ishikawa T, Kumada M, Yazaki Y. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. *Nature* 368: 703-710, 1994. (\*equal contribution)
  14. Maemura K, Kurihara H, Kurihara Y, Nagai R, Yazaki Y. Isolation and characterization of vascular endothelial cells derived from mice lacking endothelin-1. *Biochem. Biophys. Res. Commun.* 201: 538-545, 1994.
  15. Maemura K, Kurihara Y, Morita H, Kurihara H, Yazaki Y. Renal endothelin and hypertension - reply. *Nature* 372: 50, 1994.
  16. Morita T, Kurihara H, Maemura K, Yoshizumi M, Nagai R, Yazaki Y. Role of Ca<sup>2+</sup> and protein kinase C in shear stress-induced actin depolymerization and endothelin-1 gene expression. *Circ. Res.* 75: 630-636, 1994.
  17. Harats D\*, Kurihara H\*, Belloni P, Oakley H, Ziober A, Ackley D, Cain G, Kurihara Y, Lawn R, Sigal E. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. *J. Clin. Invest.* 95: 1335-1344, 1995. (\*equal contribution)
  18. Kurihara Y, Kurihara H, Oda H, Maemura K, Nagai R, Ishikawa T, Yazaki Y. Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. *J. Clin. Invest.* 96: 293-300, 1995.
  19. Maemura K, Kurihara H, Kurihara Y, Oda H, Ishikawa T, Copeland NG, Gilbert DJ, Jenkins NA, Yazaki Y. Sequence analysis, chromosomal location and developmental expression of the mouse preproendothelin-1 gene. *Genomics* 31: 177-184, 1996.
  20. Kuwaki T, Cao W-H, Kurihara Y, Kurihara H, Ling G-Y, Onodera M, Ju K-H, Yazaki Y, Kumada M. Impaired ventilatory responses to hypoxia and hypercapnia in mutant mice deficient in endothelin-1. *Am. J. Physiol.* 270: R1279-R1286, 1996.
  21. Reid K, Turnley AM, Maxwell GD, Kurihara Y, Kurihara H, Bartlett PF, Murphy M. Multiple roles for endothelin 3 in melanocyte development: Regulation of progenitor number and stimulation of differentiation. *Development* 122: 3911-3919, 1996.
  22. Minamino T, Kurihara H, Takahashi M, Shimada K, Maemura K, Oda H, Ishikawa T, Uchiyama T, Tanzawa K, Yazaki Y. Endothelin converting enzyme (ECE-1) expression in the rat vascular injury model and human coronary atherosclerosis. *Circulation* 95: 221-230, 1997.
  23. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Horiuchi S, Takahashi K, Kruijt JK, van Berkel TJC, Steinbrecher UP, Ishibashi S, Maeda N, Gordon S, Kodama T. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. *Nature* 386: 292-296, 1997.
  24. Kurihara H, Kurihara Y, Maemura K, Yazaki Y. The role of endothelin-1 in cardiovascular development. *Ann. NY. Acad. Sci.* 811: 168-177, 1997.
  25. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. *Circulation* 95: 2032-2036, 1997.
  26. Kuwaki T, Kurihara H, Cao WH, Kurihara Y, Unekawa M, Yazaki Y, Kumada M: Physiological role of brain endothelin in the central autonomic control: from neuron to knockout mice. *Prog. Neurobiol.* 51: 545-579, 1997.
  27. Nagase T, Kurihara H, Kurihara Y, Aoki-Nagase T, Fukuchi Y, Yazaki Y, Ouchi Y. Airway hyperresponsiveness to methacholine in mutant mice deficient in endothelin-1. *Am. J. Respir. Crit. Care Med.* 157: 560-564, 1998.
  28. Kitano Y, Kurihara H, Kurihara Y, Maemura K, Ryo Y, Yazaki Y, Harii K. Gene expression of bone matrix proteins and endothelin receptors in endothelin-1-deficient mice revealed by in situ hybridization. *J. Bone Miner. Res.* 13: 237-244, 1998.
  29. Thomas T, Kurihara H, Yamagishi H, Kurihara Y, Yazaki Y, Olson EN, Srivastava D. A signaling cascade involving endothelin-1, dHAND and Msx1 regulates development of neural crest-derived branchial arch mesenchyme. *Development* 125: 3005-3014, 1998.
  30. Morita H, Kurihara H, Tsubaki S, Sugiyama T, Hamada C, Kurihara Y, Shindo T, Oh-hashii Y, Kitamura K, Yazaki Y. Methylenetetrahydrofolate

- reductase (MTHFR) gene polymorphism and ischemic stroke in Japanese. *Arterioscler. Thromb. Vasc. Biol.* 18: 1465-1469, 1998.
31. Ling GY, Cao WH, Onodera M, Ju KH, Kurihara H, Kurihara Y, Yazaki Y, Kumada M, Fukuda Y, Kuwaki T. Renal sympathetic nerve activity in mice: comparison between mice and rats and between normal and endothelin-1 deficient mice. *Brain Res.* 808: 238-249, 1998.
  32. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, Sakoda T, Kurihara H, Yazaki Y, Yokoyama M. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. *J. Clin. Invest.* 102: 2061-2071, 1998.
  33. Morita H, Kurihara H, Sugiyama T, Kurihara Y, Shindo T, Oh-hashii Y, Yazaki Y. D919G polymorphism of the methionine synthase gene. Association with homocysteine metabolism and late-onset vascular diseases in the Japanese population. *Arterioscler. Thromb. Vasc. Biol.* 19: 298-302, 1999.
  34. Kuwaki T, Ling GY, Onodera M, Ishii T, Nakamura A, Ju KH, Cao WH, Kumada M, Kurihara H, Kurihara Y, Yazaki Y, Ohuchi T, Yanagisawa M, Fukuda Y. Endothelin in the central control of cardiovascular and respiratory functions. *Clin. Exp. Pharmacol. Physiol.* 26: 989-994, 1999.
  35. Kurihara H, Kurihara Y, Nagai R, Yazaki Y. Endothelin and neural crest development. *Cell. Mol. Biol.* 45: 639-651, 1999.
  36. Nagase T, Kurihara H, Kurihara Y, Aoki-Nagase T, Nagai R, Ouchi Y. Disruption of ET-1 gene enhances pulmonary responses to methacholine via functional mechanism in knockout mice. *J. Appl. Physiol.* 87: 2020-2024, 1999.
  37. Shindo T, Kurihara H, Maemura K, Kurihara Y, Kuwaki T, Izumida T, Minamino N, Ju K-H, Morita H, Oh-hashii Y, Kumada M, Kangawa K, Nagai R, Yazaki Y. Hypotension and resistance to lipopolysaccharide-induced shock in transgenic mice overexpressing adrenomedullin in their vasculature. *Circulation* 101: 2309-2316, 2000.
  38. Kurihara Y\*, Kurihara H\*, Morita H, Cao W-H, Ling G-Y, Kumada M, Kimura S, Nagai R, Yazaki Y, Kuwaki T. Role of endothelin-1 in stress response in the central nervous system. *Am. J. Physiol.* 279: R515-R521, 2000. (\*equal contribution)
  39. Shindo T, Kurihara H, Kuno K, Yokoyama H, Wada T, Kurihara Y, Imai T, Wang Y, Ogata M, Oh-hashii Y, Morita H, Ishikawa T, Nagai R, Yazaki Y, Matsushima K. ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility and organ morphology and function. *J. Clin. Invest.* 105: 1345-1352, 2000.
  40. Harats D, Shaish A, George J, Mulkins M, Kurihara H, Levkovitz H, Sigal E. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. *Arterioscler. Thromb. Vasc. Biol.* 20: 2100-2105, 2000.
  41. Morita H, Kurihara H, Yoshida S, Saito Y, Shindo T, Oh-hashii Y, Kurihara Y, Yazaki Y, Nagai R. Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury. *Circulation* 103: 133-139, 2001.
  42. Ho MCY, Lo ACY, Kurihara H, Yu ACH, Chung SK. Endothelin-1 protects astrocytes from hypoxic/ischemic injury. *FASEB J.* 15: 618-626, 2001.
  43. Imai T, Morita T, Shindo S, Nagai R, Yazaki Y, Kurihara H, Suematsu M, Katayama S. Vascular smooth muscle cell-directed overexpression of human heme oxygenase-1 elevates blood pressure through attenuation of NO-induced vasodilation in mice. *Circ. Res.* 89:55-62, 2001.
  44. Yamaguchi Y, Fukuhara S, Nagase T, Tomita T, Hitomi S, Kimura S, Kurihara H, Ouchi Y. A novel mouse  $\beta$ -defensin, mBD-6, predominantly expressed in skeletal muscle. *J. Biol.Chem.* 276:31510-31514, 2001.
  45. Imai Y, Shindo T, Maemura K, Kurihara Y, Nagai R, Kurihara H. Evidence for the physiological and pathological roles of adrenomedullin from genetic engineering in mice. *Ann. NY. Acad. Sci.* 947:26-34, 2001.
  46. Shindo T, Kurihara Y, Nishimatsu H, Moriyama N, Kakoki M, Wang Y, Imai Y, Ebihara A, Kuwaki T, Ju K-H, Minamino N, Kangawa K, Ishikawa T, Fukuda M, Akimoto Y, Kawakami H, Imai Y, Imai T, Morita H, Yazaki Y, Nagai R, Hirata Y, Kurihara H. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. *Circulation* 104:1964-1971, 2001.
  47. Oh-hashii Y, Shindo T, Kurihara Y, Imai T, Wang Y, Morita H, Imai Y, Kayaba Y, Nishimatsu H, Suematsu Y, Hirata Y, Yazaki Y, Nagai R, Kuwaki T, Kurihara H. Elevated sympathetic nervous activity in mice deficient in aCGRP. *Circ. Res.* 89:983-990, 2001.
  48. Shindo T, Kurihara H, Maemura K, Kurihara Y, Ueda O, Suzuki H, Kuwaki T, Ju K-H, Wang Y, Morita H, Oh-hashii Y, Kumada M, Nagai R, Yazaki Y, Kimura K. Renal damage and salt-dependent hypertension in aged transgenic mice overexpressing endothelin-1. *J. Mol. Med.* 80:105-116, 2002.
  49. Imai Y, Shindo T, Sata M, Memura K, Saito Y, Akishita M, Osuga J, Ishibashi S, Tobe K, Maekawa H, Oh-hashii Y, Morita H, Kurihara Y, Yazaki Y, Nagai R, Kurihara H. Resistance to neointimal hyperplasia and fatty streak formation in adrenomedullin overexpression mice. *Arterioscler. Thromb. Vasc. Biol.* 22: 1310-1315, 2002.
  50. Yamaguchi Y, Nagase T, Makita R, Fukuhara S, Tomita T, Tominaga T, Kurihara H, Ouchi Y. Identification of multiple novel epididymis-specific  $\beta$ -defensin isoforms in humans and mice. *J. Immunol.* 169: 2516-2523, 2002.